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PENDEDAHAN CALON BARU PLURIPOTENSI DAN KOMPLEMENTASI 
ANTARA SPESIES GEN DENGAN PERBANDINGAN TRANSKRIPTOMIK 
DI MANUSIA DAN IKAN ZEBRA 
ABSTRAK 
Profil transkriptom pluripotensi manusia telah dikenali dengan menggunakan 
DNA microarray, expressed sequence tag, penjujukan selari besar-besaran, serial 
analysis of gene expression (SAGE) and SAGE terbalik. Untuk mendedahkan gen 
lain yang terlibat dalam pluripotensi manusia, profile transckriptom sel pucuk embrio 
(ES) and sel karsinoma embrio (EC) manusia dikaji dengan menggunakan Jujukan 
Illumina Next Generation. Pendedahan gen lain ini akan menyediakan gambaran 
komprehensif tentang pluripotensi manusia. Pengajian transkriptom ini menyokong 
penemuan sebelumnya tentang gen pluripotensi yang dikenali, termasuk POU5F1, 
SOX2, NANOG dan LIN28A. Selain itu, gen baru dan bahagian transkripsi baru yang 
diekspres khususnya pada sel ES/EC manusia juga dikenali. Transkip ini besar 
kemungkinan terlibat dalam pengekalan pluripotensi manusia. Dengan itu, data 
transkriptom manusia ini menyumbang untuk pemahaman yang lebih baik tentang 
pluripotensi manusia dan juga memajukan anotasi rujukan manusia semasa. 
Walaupun POU5F1 tidak boleh dikecualikan untuk pluripotensi dalam vertebrata, 
pou5f1 ikan zebra tidak boleh mengekalkan atau mengaruh pluripotensi dalam 
vertebrata tinggi dalam laporan sebelumnya. Fungsi zebrafish pou5f1 yang tidak 
dipelihara dalam pluripotensi mencetuskan pengajian pemeliharaan fungsi ini. Gen 
POU5F1, SOX2 dan NANOG adalah teras transkripsi pengawal dalam rangkaian 
pluripotensi. Dalam pengajian pemeliharaan fungsi ini, POU5F1, SOX2, NANOG 
dan LIN28A manusia boleh memprogram sel fibroblast manusia kepada sel 
pluripotensi pucuk aruhan (iPS) manusia ke takat tertentu tetapi ortolog ikan zebra 
xxiv 
 
tidak boleh. Dengan itu, fungsi pou5f1, sox2, nanog dan lin28a dalam aruhan 
pluripotensi adalah tidak dipelihara pada ikan zebra. Ketidakupayaan pou5f1, sox2, 
nanog and lin28a ikan zebra dalam aruhan pluripotensi menggesakan pengajian 
profil transkriptom pluripotensi dalam ikan zebra denggan menggunakan Jujukan 
Illumina Next Generation pada sel pucuk ikan zebra (ZES). Dataset transcriptom 
awam pada embrio awal ikan zebra juga termasuk dalam analisis untuk menyediakan 
gambaran menyeluruh tentang pluripotensi dalam ikan zebra. Sepadan dengan 
pengajian pemeliharaan fungsi sebelumnya, teras faktor pluripotensi pou5f1, sox2 
dan nanog tidak diekspres atau diekspres pada tahap yang amat rendah pada ZES 
tetapi diekspres pada tahap yang tinggi pada embrio awal ikan zebra. Pemeliharaan 
ekspresi sesetengah ortholog gen pluripotensi manusia dan ekspresi sesetengah gen 
sasaran pou5f1 ikan zebra pada tahap tinggi pada ZES membayangkan lebihan fungsi 
pou5f1, sox2 dan nanog untuk pluripotensi ikan zebra dan mekanisma lain 
kemungkinan terlibat dalam pengekalan pluripotensi in vitro pada ikan zebra. Gen 
nop14, zgc:109782 dan tuba8l4 dan transkrip hypotetikal novel pada loci 
chr12:17512223-17550720, chr12:20132645-20193454 dan chr13:11761814-
11775511 besar kemungkinan terlibat dalam pluripotensi ikan zebra. 
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UNCOVERING CANDIDATE NOVEL PLURIPOTENCY AND CROSS-
SPECIES COMPLEMENTATION GENES BY COMPARATIVE 
TRANSCRIPTOMICS IN HUMAN AND ZEBRAFISH 
ABSTRACT 
The transcriptome profile of human pluripotency has been revealed using 
DNA microarray, expressed sequence tag, massively parallel signature sequencing, 
serial analysis of gene expression (SAGE) and reverse SAGE. To discover additional 
genes involved in human pluripotency, the transcriptome profile of human 
embryonic stem (ES) and embryonic carcinoma (EC) cells was studied using 
Illumina Next Generation Sequencing. The discovery of these additional genes will 
provide a more comprehensive overview of human pluripotency. This transcriptome 
study supported the previous findings of known pluripotency genes, including 
POU5F1, SOX2, NANOG and LIN28A. In addition, additional genes and novel 
transcribed regions specifically expressed in human ES/EC cells were also revealed. 
These transcripts are likely to be involved in the maintenance of human pluripotency. 
Thus, this human transcriptomic data contributes to a better understanding of the 
human pluripotency as well as improves the current human reference annotation. 
Though POU5F1 is indispensable for pluripotency in vertebrates, zebrafish pou5f1 
could not maintain nor induce pluripotency in higher vertebrates in previous reports. 
The non-conserved roles of zebrafish pou5f1 in pluripotency triggered this functional 
conservation study. Pluripotency genes POU5F1, SOX2 and NANOG are core 
transcriptional regulators of pluripotency network. In this functional conservation 
study, human POU5F1, SOX2, NANOG and LIN28A could reprogram human 
fibroblast to human induced pluripotent stem (iPS) cells to certain extent but not 
zebrafish orthologues of these genes. Thus, the roles of pou5f1, sox2, nanog and 
xxvi 
 
lin28a in the induction of pluripotency were not conserved in zebrafish. The inability 
of zebrafish pou5f1, sox2, nanog and lin28a in the induction of pluripotency 
prompted the transcriptome profile study of pluripotency in zebrafish using Illumina 
Next Generation Sequencing on zebrafish ES-like cells (ZES). Public transcriptome 
data sets on zebrafish early embryos were also included in the analysis to provide a 
comprehensive overview of pluripotency in zebrafish. Corresponding to the previous 
functional conservation study, core pluripotency factors pou5f1, sox2 and nanog 
were not expressed or expressed at extremely low levels in ZES but highly expressed 
in zebrafish early embryos. The conserved expression of some other orthologues of 
mammalian pluripotency genes and the high expression of some zebrafish pou5f1 
target genes in ZES implied the functional redundancy of pou5f1, sox2 and nanog in 
zebrafish pluripotency and other mechanisms might be involved in the maintenance 
of in vitro pluripotency in zebrafish. Genes nop14, zgc:109782 and tuba8l4 and 
novel hypothetical transcripts at loci chr12:17512223-17550720, chr12:20132645-
20193454 and chr13:11761814-11775511 are likely to be involved in zebrafish 
pluripotency. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1       Research background 
Human pluripotency gene candidates have been identified in different 
transcriptome studies using DNA microarray, expressed sequence tag (Bhattacharya 
et al., 2004), massively parallel signature sequencing (Wei et al., 2005), serial 
analysis of gene expression (SAGE) (Richards et al., 2004) and reverse SAGE 
(Richards et al., 2006).  Some of these candidate genes were functionally proven 
their significance in the maintenance of pluripotency. In each transcriptomic study, 
additional potential genes involved in pluripotency were revealed. With the 
introduction of Next-Generation Sequencing, a major transformation was seen in the 
transcriptomic area with enormous throughput in the gathering of genomic and 
transcriptomic information. Next-Generation Sequencing allows detection and 
sequencing of all expressed transcripts without prior knowledge of transcript 
sequence and reference annotation (Morozova et al., 2009). With this advance, we 
hypothesized that an unprecedented exploration could be achieved in human 
pluripotency with the discovery of additional annotated and novel hypothetical 
pluripotency transcripts. Novel hypothetical transcripts mean transcripts that could 
map to reference genome, but they have not been annotated in reference transcript 
database. 
 
2 
 
POU5F1, SOX2 and NANOG (Boyer et al., 2005) are core transcriptional 
regulators in pluripotency network in vertebrates. Various cross-species 
complementation experiments were conducted between different species both in vitro 
and in vivo to reveal the cross-species complementation of these genes in vertebrate. 
The interchangeable function of POU5F1 and NANOG from different species in the 
maintenance and induction of pluripotency in mouse ES cells in vitro (Morrison, 
2006, Lavial et al., 2007, Niwa et al., 2008, Theunissen et al., 2011, Schuff et al., 
2012b) and the ability of mouse Pou5f1, Sox2 and Klf4 to reprogram Xenopus 
tadpole muscle to proliferating cell clusters in vivo (Vivien et al., 2012) demonstrated 
the cross-species complementation of pluripotency factors in vertebrates and the 
induction of pluripotency could be induced in distant and diverse groups of animals. 
Nonetheless, interaction necessary to maintain pluripotency in mouse and Xenopus 
was lost in zebrafish. Zebrafish pou5f1 could not rescue Pou5f1-deficient mouse ES 
cells (Morrison, 2006, Niwa et al., 2008) nor induce pluripotency in mouse (Tapia et 
al., 2012) and zebrafish pou5f1 showed very little rescue in PouV depletion 
phenotype in Xenopus (Morrison, 2006, Lavial et al., 2007). In addition, zebrafish 
pou5f1 transcription was reported to be absent in zebrafish transient ES-like culture 
but present abundantly in zebrafish oblong stage embryos which is the embryonic 
stage for the derivation of zebrafish ES-like cells (ZES). The unusual expression and 
the inability of zebrafish pou5f1 in the maintenance and induction of pluripotency 
triggered us to study the cross-species complementation of pluripotency genes, 
POU5F1, SOX2, NANOG and LIN28A in human and zebrafish via human induced 
pluripotent stem (iPS) cell reprogramming assay. LIN28A was included in this assay 
to increase the reprogramming efficiency (Yu et al., 2007). 
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From the reprogramming assay, zebrafish pou5f1, sox2, nanog and lin28a 
could not induce pluripotency in human. Moreover, the expression of pou5f1 and 
nanog orthologues was undetectable in ZES but was high in zebrafish early embryos. 
These previous findings prompted us to conduct transcriptome profiling on ZES with 
full developmental potency using Illumina Next-Generation Sequencing approach. 
To gain a thorough profile on zebrafish pluripotency, transcriptomic data of zebrafish 
early embryos from public database (Aanes et al., 2011) was included in the analysis 
to reveal the molecular signatures of pluripotency in zebrafish.  
 
1.2       Objectives of this study 
The objectives of this study are: 
I. To identify the pluripotency gene candidates in human by transcriptome 
analysis of human ES and EC cell lines profiled using RNA-seq. 
II. To study the cross-species complementation of pluripotency genes 
POU5F1, SOX2, NANOG and LIN28A in human and zebrafish using 
human iPS cell reprogramming assay. 
III. To identify the pluripotency gene candidates in zebrafish using the RNA-
seq data from ZES cells and early embryos. 
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CHAPTER 2 
LITERATURE REVIEW 
 
 
2.1       Pluripotency 
Pluripotency has different definitions by different scientists. The definition of 
pluripotency which is widely accepted is the competency to self-renew indefinitely 
and to differentiate into derivatives of all three embryonic germ layers both in vivo 
and in vitro. This competency is a dynamic state influenced by cellular 
microenvironment which affects the differentiation capacity of the cells into 
functional tissues (Smith et al., 2009). Pluripotency is maintained by a globally open 
chromatin state of cells.  This open chromatin state is accessible to transcriptional 
machinery and other factors maintaining a local silencing of lineage-specific genes 
until differentiation is initiated (Gaspar-Maia et al., 2011).  
Pluripotency is classified into two phases: naïve and primed. Mouse inner cell 
mass from preimplantation embryos and embryonic stem (ES) cells derived from 
mouse inner cell mass constitute naïve pluripotency or ground state. Mouse epiblast 
cells from postimplantation embryos, mouse Epistem cells (EpiSC) derived from the 
epiblast cells and human embryonic stem cells (hESC) constitute primed 
pluripotency. Mouse EpiSC and hESC are similar in morphological traits, epigenetic, 
genetic, culture conditions and signaling requirements (Nichols and Smith, 2009). 
Epigenetic signatures and transcriptional network regulating pluripotency are 
conserved in human and mouse. The same four transcription factors POU5F1, SOX2, 
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KLF4 and c-MYC could be used in the reprogramming of somatic cells to iPS cells in 
these two species (Johnson et al., 2008). In spite of these similarities, hESC are 
different from mouse ES cells in morphology, clonogenicity, global gene expression 
profile, downstream target genes of POU5F1, SOX2 and NANOG, culture condition 
and differentiation behavior (Johnson et al., 2008, Nichols and Smith, 2009). SSEA1 
is expressed in undifferentiated mouse ES cells, but is expressed in differentiated 
hESC. In contrast, SSEA3 and SSEA4 are expressed in undifferentiated hESC, but 
are expressed in differentiated mouse ES cells (Draper et al., 2002). In term of 
culture condition, hESC require Activin/Nodal and fibroblast growth factor (FGF) 
while mouse ES cells require leukemia inhibitory factor (LIF) and bone 
morphogenetic protein 4 (BMP4) in the absence of feeder cells for the maintenance 
of pluripotency. LIF signaling could not maintain self-renewal of hESC and BMP4 
induces differentiation of hESC to trophoblast (Vallier, 2005, Daheron et al., 2004, 
Xu et al., 2002). These differences are thought to be developmental distinction 
between naïve and primed pluripotency rather than species-specific difference 
(Nichols and Smith, 2009).   
Mouse ES cells are distinct from mouse EpiSC in culture condition, growth 
factor dependence, gene expression, epigenetic status and function (Nichols and 
Smith, 2009, Guo et al., 2009). The culture of mouse ES cells requires cytokine LIF 
but the culture of mouse EpiSC requires Activin and FGF but not LIF (Brons et al., 
2007). Mouse ES cells could be converted to EpiSC in response to Activin A and 
FGF2 with the resulting EpiSC show downregulation of Klf4. Mouse EpiSC could be 
converted to mouse ES cells by overexpression of Klf4 and culture in ES cell media 
containing Mek/Erk inhibitor, Gsk3 inhibitor and LIF. The resulting EpiSC–iPS cells 
exhibit undifferentiated morphology, express ES cell specific transcripts and show 
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downregulation of lineage specification markers. Both X-chromosomes are activated 
in mouse ES cells while one of the X-chromosome is silenced in mouse EpiSC. 
Mouse ES cells could form chimera and germ-line transmission but mouse EpiSC 
could not, after injecting the cells into blastocysts. The distinct differentiation ability 
could be explained by different in X-chromosome silencing. In addition, mouse 
EpiSC were argued to be differentiated from mouse ES cells developmentally, 
functionally and epigenetically (Guo et al., 2009). Thus, mouse EpiSC are more 
developmental restricted than mouse ES cells (Nichols and Smith, 2009). In spite of 
the differences between mouse ES and EpiSC, these two cells are similar in the 
expression of core pluripotency genes Pou5f1, Sox2, Nanog and in the ability to 
differentiate into three germ layers via embryoid body and teratoma formation. 
Pou5f1 and Nanog are two transcriptional regulators that are required for the 
establishment and maintenance of pluripotent compartments in early embryos 
(Nichols and Smith, 2009). 
 
2.1.1     Pluripotency in fish 
In order to explore the mechanism of pluripotency genes for therapeutic 
application, it is important to understand the pluripotency gene in vivo. Fish is an 
excellent model to study in vivo pluripotency. Fish could complement mouse model 
by the combination of embryological, genetic and molecular analysis. The large 
number of transparent fish embryos, ex utero development and easier gene function 
manipulation enable rapid analysis of pluripotency genes in early embryonic 
development and discovery of new molecules and mechanisms that govern the 
pluripotency in vivo (Sanchez-Sanchez et al., 2011).  
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The discovery of pou5f1 and nanog homologues in medaka and zebrafish 
genomes indicates that the key pluripotency genes are not exclusive to mammals 
(Camp et al., 2009, Sánchez-Sánchez et al., 2010). Cross-species complementation 
assay of pluripotency genes between fish and mammals are required to reveal the 
extent of cross-species complementation of these genes in vertebrates. Functional 
characterization of pluripotency genes in teleost could reveal the evolution of these 
genes in vertebrate lineage and clarify some discrepancies in gene function between 
mouse and human (Sanchez-Sanchez et al., 2011).  
 
2.1.2    Assessment of pluripotency 
Both undifferentiated state and differentiation potential are assayed in the 
assessment of pluripotency. The assessments of undifferentiated state are cell 
morphology, cell cycle, gene expression and epigenetics. Undifferentiated cells have 
prominent nucleoli, high nuclear-to-cytoplasm ratio and they form multi-layered 
colonies (Smith et al., 2009). In addition, undifferentiated cells have abbreviated G1 
phase of cell cycle and they proliferate rapidly (Becker et al., 2006). The 
undifferentiated cells could also be assessed by expression of alkaline phosphatase, 
telomerase, cell surface antigens and three core pluripotency factors: OCT4 (Nichols 
et al., 1998), SOX2 and NANOG (Mitsui, et al., 2003). The epigenetic status of 
undifferentiated cells could be assessed by bisulfite sequencing of OCT4 and 
NANOG gene promoters (Wernig et al., 2007) and expression of unique set of 
microRNA (Houbaviy et al., 2003).  
The assessment of differentiation potential could be assayed both in vitro and 
in vivo. For in vitro differentiation potential, directed differentiation using specific 
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culture conditions and growth factors (Trounson, 2006) and differentiation via 
embryoid bodies formation (Itskovitz-Eldor et al., 2000) into cell lineage 
representatives of each germ layer (ectoderm, mesoderm and endoderm) could be 
assessed. For in vivo differentiation potential, the capability of a cell to form 
chimera, tetraploid blastocyst and teratoma (Smith et al., 2009) could be assayed. 
Chimera and tetraploid blastocyst complementation are the gold standards for 
the characterization of pluripotency (Smith et al., 2009). Chimera is formed by 
injection of pluripotent cells into normal 2n blastocyst. These pluripotent cells will 
then differentiate into various tissues when blastocyst develops into an adult (Okita 
et al., 2007). Tetraploid blastocyst-complemented embryo is formed by injection of 
pluripotent cells into 4n blastocyst. This 4n blastocyst is formed by the fusion of 2 
cells and is developmentally defective. Thus, pluripotent cells compensate for this 
developmental defectiveness and form the entire organism (Nagy et al., 1993). 
Teratoma is a less stringent criterion to assess pluripotency in vivo (Smith et al., 
2009). Teratoma is a non-malignant tumor consisting of tissues from all three germ 
layers. This tumor is formed by implantation of pluripotent ES cells into immuno-
compromised mouse (Wesselschmidt, 2011). Terotoma is used to assess pluripotency 
of human pluripotent cells in vivo as both chimera and tetraploid complementation 
are not ethically feasible in human. The standard criteria of human pluripotent cells 
established by the US National Institutes of Health (NIH) are the ability of cells to 
proliferate indefinitely, the expression of pluripotent transcription factors and cell 
surface markers and the formation of teratoma containing derivatives of three germ 
layers (Smith et al., 2009). 
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2.2       Sources of pluripotent cells 
Pluripotent cells can be obtained from the following sources or processes: 
inner cell mass of pre-implantation blastocyst (Evans and Kaufman, 1981, Martin, 
1981, Thomson, 1998), teratocarcinoma (Andrews et al., 2005), somatic cell nuclear 
transfer (SCNT) (Gurdon, 1968, Gurdon and Laskey, 1970), cellular hybridization 
(Miller and Ruddle, 1976, Tada et al., 1997, Tada et al., 2001, Tada et al., 2003, 
Cowan et al., 2005) and reprogramming (Takahashi and Yamanaka, 2006, Takahashi 
et al., 2007, Yu et al., 2007). The pluripotent cells of teratocarcinoma are known as 
EC cells (Andrews et al., 2005). Blastomeres of inner cell mass isolated from pre-
implantation blastocyst and cultured in vitro are known as ES cells (Evans and 
Kaufman, 1981, Martin, 1981, Thomson, 1998). SCNT is a technique in which 
somatic cell nucleus is injected into enucleated egg and host cell cytoplasm 
reprograms the epigenome of somatic cell to pluripotent state (Gurdon, 1968, Gurdon 
and Laskey, 1970). Cellular hybridization is the fusion of somatic cells and EC 
(Miller and Ruddle, 1976), embryonic germ (EG) (Tada et al., 1997) or ES cells 
(Tada et al., 2001, Tada et al., 2003, Cowan et al., 2005) forming pluripotent hybrid 
cells. Reprogramming is the conversion of somatic cells into iPS cells by the 
overexpression of transcription factors or the use of small molecules (Takahashi and 
Yamanaka, 2006, Takahashi et al., 2007, Yu et al., 2007, Dey and Evans, 2011, Yuan 
et al., 2011). 
 
2.2.1    Embryonic stem (ES) cells 
Embryonic stem (ES) cells are cells derived from the inner cell mass of 
blastocysts. These cells are pluripotent which are capable to self-renew and to 
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differentiate. ES cells self-renew to produce more stem cells when cultured in 
appropriate condition and differentiate to generate derivatives of all three embryonic 
germ layers both in vivo and in vitro (Evans and Kaufman, 1981; Martin, 1981; 
Thomson, 1998). During differentiation of ES cells, phenotypic and molecular 
changes occurred hierarchically, with epiblast cells formed first, followed by germ 
layers ectoderm, mesoderm and endoderm and subsequently somatic cells (Gaspar et 
al., 2012). 
The first embryo-derived pluripotent cells were derived from mouse by two 
independent groups in 1981 (Evans and Kaufman, 1981, Martin, 1981). After 17 
years since derivation of mouse ES cells, the first hESC was derived in 1998. These 
pluripotent hESC display normal karyotypes, express high telomerase activity and 
cell surface markers and capable of forming teratoma containing derivatives from 
three embryonic germ layers (Thomson, 1998). Human ES cells provide an excellent 
cell source for human development study, drug discovery and regenerative medicine. 
However, its derivation from human early embryos raises ethical issues and 
controversies. The reprogramming of somatic cells to ES-like cells serves as an 
alternative to solve this disputation (Orkin, 2005).  
 
2.2.1.1 Fish ES-like cells 
Fish ES-like cells are commonly derived from blastula stage embryos. The 
inner cell mass at this embryonic stage are pluripotent and developmental 
undetermined (Robles et al., 2011, Wang et al., 2011b). These cells are capable of 
forming germline chimera (Fan et al., 2004b). ES-like cells were derived and 
characterized in medaka (Hong and Schartl, 2006), zebrafish (Fan et al., 2004a, Fan 
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et al., 2004b, Fan and Collodi, 2006), gilt-head bream (Bejar et al., 2002; 
Parameswaran et al., 2012), sea perch (Chen et al., 2003), Asian sea bass 
(Parameswaran et al., 2007), Indian major carp (Dash et al., 2010) and Atlantic cod 
(Holen et al., 2010). These fish ES-like cells share in vitro properties with mouse ES 
cells. In addition, it is possible to derive embryonic cell cultures from stages earlier 
than blastula stage (Li et al., 2011) or at gastrula stage (Chen et al., 2004). Fish stem 
cell serves as an excellent tool to study in vivo and in vitro stem cell biology as 
observation of ES cell-derived chimeras is feasible with the external and transparent 
fish embryos. 
 
2.2.2    Embryonic carcinoma (EC) cells 
Embryonic carcinoma (EC) cells are the undifferentiated cells derived from 
teratocarcinoma. Teratocarcinoma is a germ cell tumor consists of both differentiated 
tissues from three embryonic germ layers and undifferentiated, malignant cells which 
are known as EC cells. This tumor commonly occurred in testis which is known as 
testicular germ cell tumour (TGCT) (Andrews, 2002). TGCT originates from a 
carcinoma in situ (CIS) stage before the tumor could be histologically classified into 
seminoma or non-seminoma. Seminoma is composed of homogeneous cells which 
resemble primordial germ cells (PGC) while non-seminoma is composed of 
teratocarcinomas with undifferentiated EC cells, yolk sac carcinomas (YSCs) and 
choriocarcinomas (Oosterhuis and Looijenga, 2005) (Figure 2.1).  
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Figure 2.1: Development of teratocarcinoma. Simplied diagram of teratocarcinoma 
development. 
 
 
EC cells were the first pluripotent cells isolated and cultured in vitro. 
(Andrews, 2002). EC cells could be categorized into pluripotent EC cells and 
nullipotent EC cells. There are several differences between these two types of EC 
cells. Pluripotent EC cells show the full capacity to differentiate into somatic tissues 
of ectodermal, mesodermal and endodermal lineages and extraembryonic tissues 
while nullipotent EC cells show limited capacity for differentiation and could only 
divide to form EC cells. In addition, nullipotent EC cells have shorter doubling time 
and higher colony forming ability than pluripotent EC cells. In the absence of feeder 
cells, pluripotent EC cells differentiate while nullipotent EC cells still could form 
colonies. When EC cells are injected into immune-compromised mouse, pluripotent 
EC cells form teratocarcinoma which is composed of EC cells and other 
differentiated cell types while nullipotent EC cells form a sac of EC cells (Pera et al., 
1989, Teshima et al., 1988). Studies on nullipotent EC cells will provide information 
on the tumorigenesis and regulation of proliferation in ES cells (Pera et al., 1989). 
Human and mouse EC cells are resemble to each other in which they have 
similar morphology, prominent nucleoli and sparse cytoplasm, grow in clusters of 
tightly packed cells and express alkaline phosphatase (Bernstine et al., 1973; Benham 
et al., 1981). In spite of these similarities, human and mouse EC are different in 
molecular and differentiation potential. In molecular, human EC cells express 
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embryonic antigen SSEA3 but not SSEA1. Conversely, mouse EC cells express 
SSEA1 but not SSEA3 (Andrews et al., 1982, Solter and Knowles, 1978). In 
differentiation potential, human EC cells have the propensity to differentiate into 
trophectoderm but this propensity is absence in mouse EC cells (Damjanov and 
Andrews, 1983).  
EC cells are important for the understanding of tumor progression, self-
renewal and differentiation in embryonic development (Andrews, 1998, Przyborski 
et al., 2004). Compared to human ES cells, human EC cells are easier to culture, does 
not require a feeder layer and almost no spontaneous differentiation (Knott et al., 
2012). Mouse ES cells are derived from 3.5 embryonic day of blastocyst while the 
cut-off time for the formation of embryo-derived teratocarcinoma is 7.5 embryonic 
day, which is too late for derivation of mouse ES cells. 
 
2.2.2.1 EC cells are malignant surrogates of ES cells 
In spite of the cancerous origin of EC cells, both ES cells and EC cells are 
similar to each other. Both ES and EC cells are capable to self-renew indefinitely and 
to differentiate. As seen in EC cells, culture-adapted ES cells also acquire karyotypic 
change upon prolonged culture in vitro, increased proliferation and decreased 
differention potential which are parallel to the malignant transformation (Baker et al., 
2007). Normal stem cells and cancer cells might use similar signaling pathways to 
control self-renewal (Reya et al., 2001). In addition, ES cells also exhibit 
tumorigenicity properties such as expression of tumor-related genes, downregulation 
of p53, a tumor suppressor gene and increased telomerase activity which allows 
indefinite proliferation (Wobus, 2010). This telomerase activity contributes to 
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immortality of both ES and EC cells (Shay et al., 2001). When ES cells are injected 
into immuno-compromised mouse, teratocarcinoma is formed. This teratocarcinoma 
contains stem cells which are similar to ES cells in morphology and expression of 
cell surface markers such as SSEA3, SSEA4, Tra-1-60 and Tra-1-81. Similar to ES 
cells, Pou5f1 knockdown in EC cells results in growth arrest and differentiation to 
trophectoderm (Niwa et al., 2000, Matin et al., 2004). Poor differentiated tumors are 
more similar to ES cells in gene expression pattern than well differentiated tumors, 
including overexpression of ES-specific genes and underexpression of Polycomb-
regulated genes (Ben-Porath et al., 2008). Furthermore, both ES and EC cells are 
capable to form chimera, though the chimera contribution of EC cells is lower than 
ES cells. The chimera formed by EC cells develops tumour and these cells are not 
germ-line transmitted (Barbaric and Harrison, 2012). The decreased differentiation 
potential of EC cells might be explained by the high aneuploidy of EC cells 
(Andrews, 2002).  
The culture adaptation of ES cells in vitro might reflect the development and 
progression of germ cell tumor in vivo (Baker et al., 2007, Harrison et al., 2007, 
Andrews et al., 2005). Thus, in vitro culture of ES cells might be developed in a way 
that is similar to the tumor progression of EC cells in vivo (Andrews et al., 2005). In 
addition, the gene expression profiles of EC cell differentiation and normal 
embryogenesis are similar to each other (Skotheim et al., 2005). As ES and EC cells 
are pertinent to each other, these two cell lines could be used as complementary tools 
to study pluripotency, differentiation, stem cell biology and cancer (Andrews et al., 
2005). 
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2.2.2.2 Human ES cells, HES3 and human EC cells, NCCIT, NT2D1 and 
GCT27C4 
HES3 (Pera et al., 2004) and NCCIT (Teshima et al., 1988, Damjanov et al., 
1993) are capable of self-renewal indefinitely and differentiate into cells of somatic 
and extraembryonic lineages. Upon injection of NCCIT cells into nude mice, tumors 
which consists of EC cells, immature somatic tissues, yolk sac tumors and 
trophoblastic giant cells are formed (Teshima et al., 1988). 
NT2D1 (NTERA-2 c1.D1) is a pluripotent human EC cell line which was 
derived from NTERA2. NTERA2 shares the expression of the marker genes and 
surface antigens with other human EC cells and human ES cells. Among them are 
POU5F1, SSEA3, SSEA4, TRA-1-60, TRA-1-81 and human alkaline phosphatase-
associated antigens (Andrews et al., 1982, Andrews et al., 1990, Thomson et al., 
1998, Reubinoff et al., 2000, Draper et al., 2002). NT2D1 are flattened cells with a 
high nuclear-to-cytoplasmic ratio and prominent nucleoli. NT2D1 remains 
undifferentiated in the absence of feeder layer. In addition, NT2D1 could form 
embryoid body-like structures. Upon induction, NT2D1 could be differentiated into 
neuroectodermal and mesodermal derivatives (Andrews, 1984, Simões and Ramos, 
2007). 
GCT27C4 is a nullipotent human EC cell line (Pera et al., 1989) derived from 
a multipotent clone, GCT27. Both GCT27 and GCT27C4 cells express surface 
antigens SSEA3 and SSEA4 (Pera et al., 1987, Pera et al., 1989). GCT27C4 is 
predominantly hypotriploid. In the absence of feeder cells, GCT27C4 could form 
colonies with high efficiency. Upon injection of GCT27C4 into nude mice, tumours 
consisted of only EC cells are formed (Pera et al., 1989).  
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2.2.3    Induced pluripotent stem (iPS) cells 
Induced pluripotent stem (iPS) cells are pluripotent cells reprogrammed from 
somatic cells by the overexpression of a set of transcription factors which are highly 
expressed in ES cells (Takahashi and Yamanaka, 2006, Takahashi et al., 2007). 
During reprogramming, reprogramming factors activate endogenous pluripotency 
genes and repress lineage differentiation genes. iPS cells are useful in differentiation 
studies, drug screening and regenerative medicine (Yu and Thomson, 2008). 
Both adult progenitor and terminally differentiated cells could be 
reprogrammed to iPS cells (Dey and Evans, 2011) with reprogramming efficiency 
increases with immaturity of the starting cell type (Eminli et al., 2009). Mouse adult 
neural stem cells represent an intermediate state between pluripotent and 
differentiated cells. These neural stem cells express alkaline phosphatase and SSEA1 
and could be reprogrammed earlier and more efficient than mouse embryonic 
fibroblast. Overexpression of Pou5f1 alone is sufficient to induce pluripotency in 
mouse adult neural stem cells (Kim et al., 2009b). In addition to differentiation status 
of somatic cells, somatic cells from younger subjects accumulate minimal of somatic 
mutations compared to cells from older subjects and these cells represent 
advantageous cell source for reprogramming (Panepucci et al., 2012). Mouse 
embryonic fibroblast (MEF) could be reprogrammed at higher efficiency than adult 
skin cells, tail tip fibroblast, blood and cells from biopsy tissues (Rajarajan et al., 
2012).  
Somatic cell reprogramming is a progressive event in which pluripotency 
markers are expressed in sequential manner. Transgene expression from viral 
transduction is required for a minimum of 12 days in MEF cells in order to generate 
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iPS cells. During reprogramming of MEF cells, alkaline phosphatase is activated first 
on day-3 of transgene expression, followed by SSEA1 on day-9 which marks an 
intermediate stage of reprogramming. The activation of endogeneous Pou5f1 and 
Nanog which occurs late in the reprogramming process on day-16 marks the fully 
reprogrammed cells (Brambrink et al., 2008).  
iPS cells are similar to ES cells in morphology, gene expression profile, 
proliferation rate, pluripotency and epigenetic status (Zwi-Dantsis et al., 2012). iPS 
cells are capable to self-renew and to differentiate into derivatives of three germ 
layers (Yu et al., 2007). Compared to iPS cells, ES cells are still the gold standard 
and ES cells are more efficient than iPS cells in differentiating into other cell types 
(Dey and Evans, 2011). The functional differences between iPS cells and ES cells 
might be explained by both genetic and epigenetic factors. As activation level of 
modular genes are inversely proportional to the DNA methylation level,  DNA 
methylation might account as one of the epigenetic mechanism underlying distinct 
gene expression network and function between iPS and ES cells (Wang et al., 
2011a). In addition, differential methylation regions between human iPS and ES cells 
(Doi et al., 2009) also suggest that iPS and ES cells are not equivalent in some 
aspects and iPS cells have some memories of tissues origin. iPS cells might have 
heterogeneous epigenetic profiles that alter the lineage-specific differentiation (Dey 
and Evans, 2011). As the use of ES cells in clinical application raised the ethical and 
immune rejection issues (Dey and Evans, 2011), the creation of patient-specific iPS 
cells are able to resolve the use of ES cells in therapeutic medicine. However, the use 
of iPS cells in clinical application is hampered by tumorigenicity concern which 
originates from the use of viral vector and c-Myc in reprogramming and random 
integration of transgene into host genome (Jalving & Schepers, 2009). 
18 
 
In addition to in vitro reprogramming, in vivo reprogramming was carried out 
by injecting mouse Pou5f1, Sox2 and Klf4 into Xenopus tadpole tail muscle. The 
resulting proliferating cell clusters display characteristics of pluripotency: alkaline 
phosphatase staining, activation of endogeneous pluripotency genes, upregulation of 
epigenetic regulators and capable to differentiate into derivatives of three germ layers 
in vitro and neuronal and muscle phenotypes in vivo. This in vivo approach serves as 
an alternative strategy for iPS cell generation and allows the study of the influence of 
native environment on reprogramming. This study will provide a better 
understanding of the transcriptional regulatory network that controls pluripotency 
and lineage specification in vivo  (Vivien et al., 2012). 
 
2.2.3.1 Approaches for making iPS cells 
The approaches for making iPS cells involve both genomic integrating and 
non-genomic integrating methods (Lowry & Plath, 2008). 
 
2.2.3.2 Genomic integrating methods 
The genomic integrating methods are the use of retroviral and lentiviral 
vectors to deliver transcription factors (Takahashi and Yamanaka, 2006, Takahashi et 
al., 2007, Yu et al., 2007) in reprogramming. Following genomic integration, viral 
vectors allow transgenes to be expressed for a prolonged period without provoking 
immune response (Sommer and Mostoslavsky, 2010).  
These are several differences between retroviral and lentiviral vectors. 
Retroviral vector are capable to transduce dividing cells only; while lentiviral vector 
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is a subclass of retroviral vector that are capable to transduce both dividing and non-
dividing cells. Retroviral vector tends to integrate near to the transcriptional start site; 
while lentiviral vector tends to integrate within the transcriptional unit (Wu et al., 
2003). Lentiviral vector gives higher viral yield and better transduction efficiency 
than Moloney murine leukemia virus (MMuLV)-derived retroviral vector (Dick et 
al., 2011b).  
Retroviral and lentiviral transduction are the easiest approach to generate iPS 
cell (Rajarajan et al., 2012). However, the use of retroviral and lentiviral vectors 
causes random transgene integrations into host genome (Takahashi and Yamanaka, 
2006, Takahashi et al., 2007, Yu et al., 2007) which will lead to insertional 
mutagenesis, heterogeneous iPS clones and tumor formation (Dey and Evans, 2011). 
Incomplete transgene silencing has been described for both retroviral (Takahashi and 
Yamanaka, 2006) and lentiviral vectors (Brambrink et al., 2008), with silencing 
occurred more frequently with lentiviral vector (Dick et al., 2011b).  
 
2.2.3.3 Non-genomic integrating methods 
The non-genomic integrating methods are the use of adenoviral vector 
(Stadtfeld et al., 2008), plasmid transfection (Okita et al., 2008, Si-Tayeb et al., 
2010), episomal transfection of engineered synthetic factors (Wang et al., 2011c), 
synthetic modified mRNA (Warren et al., 2010), recombinant proteins (Kim et al., 
2009a, Zhou et al., 2009) and small molecules (Huangfu et al., 2008, Dey and Evans, 
2011, Esteban et al., 2010) in reprogramming. The reprogramming efficiency of 
these methods are 0.1 to 1% of that reported for retroviral method (Dick et al., 
2011b).  
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Adenoviral vector and plasmid transfection are used to transiently express 
reprogramming factors in somatic cells. This transient expression causes the 
difficulty of maintaining reprogramming factors at sufficiently high level for a 
duration which is sufficient for reprogramming. Subsequently, the reprogramming 
efficiency with these methods is much lower than the reprogramming efficiency of 
viral methods. However, these methods reduce the tumorigenicity risk of the iPS 
cells (Stadtfeld et al., 2008, Okita et al., 2008).  
Episomal transfection of engineered synthetic factors is another non-genomic 
integrating method to generate iPS cells with higher efficiency and kinetics than 
native factors. These engineered synthetic factors were synthesized by the fusion of 
potent transactivation domain of herpex simplex virus protein VP16 to transcription 
factors POU5F1, SOX2 and NANOG, respectively. The reprogramming efficiency 
and kinetics are higher with increasing copy number of VP16 fused to POU5F1. The 
fusion of VP16 to reprogramming factor elucidates the importance of transcriptional 
activation in reprogramming (Wang et al., 2011c).  
In spite of the gene transfer methods, the use of synthetic modified mRNAs 
(Warren et al., 2010) and recombinant proteins (Kim et al., 2009a, Zhou et al., 2009) 
are another non-genomic integrating methods to generate iPS cells. Synthetic 
modified mRNAs allow reprogramming of human somatic cells to iPS cells and 
direct differentiation of RNA-iPS cells to terminally differentiated myogenic cells. 
The use of modified mRNA bases protects the mRNA from degradation. The 
reprogramming efficiency and kinetics of this mRNA approach is higher than the 
gene transfer techniques (Warren et al., 2010). To create recombinant 
reprogramming proteins, the C-terminus of each reprogramming factor was fused to 
a poly-arginine protein transduction domain which could penetrate the plasma 
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membrane of somatic cells. The recombinant proteins were then transduced into 
somatic cells in four cycles. 
The use of small molecules is another non-genomic integrating method of 
reprogramming. This method eliminates insertional mutagenesis in iPS cells. Small 
molecules can substitute reprogramming factors, enhance reprogramming efficiency 
or induce epigenetics changes via restriction of chromatin modification enzymes 
(Sommer and Mostoslavsky, 2010). Small molecules target enzymes and signaling 
proteins that are involved in pluripotency and differentiation (Yuan et al., 2011).  
 
2.2.3.4 Generation of iPS cells in different species 
iPS cells were first established in mouse by Yamanaka group in 2006 with the  
overexpression of mouse pluripotency genes Pou5f1, Sox2, Klf4, c-Myc in mouse 
embryonic and adult fibroblast cells. These iPS cells are similar to ES cells in 
morphology, growth properties, expression of ES cell markers, involvement in 
embryonic development of chimera and formation of teratoma consisting of tissues 
from three germ layers (Takahashi and Yamanaka, 2006).  
Subsequently, iPS cells were established in human by Yamanaka group in 
2007 with the overexpression of human POU5F1, SOX2, KLF4 and c-MYC in human 
adult fibroblast (Takahashi et al., 2007). In the same year, Thomson group 
established human iPS cells from human somatic cells using a different combination 
of human reprogramming factors: POU5F1, SOX2, NANOG and LIN28A (Yu et al., 
2007). In agreement with the previous studies (Takahashi and Yamanaka, 2006, 
Takahashi et al., 2007), NANOG and LIN28A are dispensable for reprogramming. 
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These two genes enhance the efficiency and frequency of reprogramming. These 
human iPS cells generated by different groups are similar to human ES cells in 
morphology, proliferation, telomerase activity, expression of cell surface markers, 
epigenetic status of pluripotency genes and capable to differentiate into tissues of 
three germ layers in embryoid bodies and teratomas (Takahashi et al., 2007, Yu et 
al., 2007). Notably, POU5F1 is the only factor that is irreplaceable in 
reprogramming (Nakagawa et al., 2008). The use of different gene combinations for 
reprogramming suggests that combination of specific transcription factors could 
modulate existing gene network and epigenetic marks (Nethercott et al., 2011).  
In addition to reprogramming of human somatic cells from healthy 
individuals, iPS cells were generated from amyotrophic lateral sclerosis (ALS) 
(Dimos et al., 2008), Down syndrome (Mou et al., 2012), heart failure patients (Zwi-
Dantsis et al., 2012) and a variety of other genetic diseases (Park et al., 2008). The 
heart failure-human-iPS cells could be differentiated into cardiomyocytes (Zwi-
Dantsis et al., 2012) and ALS-human iPS cells could be differentiated into motor 
neurons (Dimos et al., 2008). 
Human and mouse reprogramming factors were used in the iPS experiments 
in different species. Human reprogramming factors were used in the reprogramming 
of adult rat primary ear fibroblasts and bone marrow cells (Liao et al., 2009), 
newborn marmoset skin fibroblast (Wu et al., 2010), adult rabbit liver and stomach 
cells (Honda et al., 2010), porcine mesenchymal stem cells (West et al., 2010), quail 
embryonic fibroblast (Lu et al., 2011), and fibroblast of two endangered species, drill 
Mandrillus leucophaeus and northern white rhinoceros Ceratotherium simum cottoni 
(Friedrich Ben-Nun et al., 2011). Mouse reprogramming factors were used in the 
reprogramming of horse fetal fibroblast (Nagy et al., 2011).  
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The reprogramming of somatic cells from different species using human and 
mouse reprogramming factors reveals a high degree of cross-species 
complementation of pluripotency gene (Rajarajan et al., 2012) and reprogramming 
process (Lu et al., 2011). Direct reprogramming using transcription factors is a 
universal strategy in distantly-related species which might include all species (Lu et 
al., 2011). In addition, comparison of iPS cells from different species could elucidate 
the key aspect of pluripotency and early development (Rajarajan et al., 2012). 
 
2.2.3.5 Characterizations of iPS cells 
Alkaline phosphatase staining, expression of endogeneous POU5F1 and 
NANOG and cell surface markers SSEA3, SSEA4, TRA-1-60 and TRA-1-81, in vitro 
tri-lineage differentiation and in vivo terotoma formation are widely used for the 
initial characterization of ES and iPS cells (Adewumi et al., 2007). 
Fully reprogrammed iPS cells are highly similar to ES cells in gene 
expression and epigenetic status. Fully reprogrammed iPS cells show complete 
transgene silencing, expression of only endogeneous genes to maintain the 
pluripotency state and form teratoma that consists of tissues of ectodermal, 
mesodermal and endodermal origins  (Chan et al., 2009, Mikkelsen et al., 2008). 
Partially reprogrammed iPS cells show an incomplete transgene silencing, expression 
of transgenes at higher level than endogenous pluripotency genes (Chan et al., 2009, 
Mikkelsen et al., 2008), activation of a distinctive subset of stem cell-related genes, 
incomplete repression of lineage-specific transcription factors, DNA 
hypermethylation at pluripotency gene loci (Mikkelsen et al., 2008) and form 
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teratoma that consists of tissues of ectodermal and mesodermal origins but not of 
endodermal origin (Chan et al., 2009). 
In human fibroblast reprogramming, bona-fide iPS cells are CD13
-
, SSEA4
+
, 
TRA-1-60
+
, NANOG
+ 
and transgene silenced. Alkaline phosphatase, SSEA4, 
hTERT, GDF3 and NANOG are not reliable markers to distinguish fully 
reprogrammed cells from partially reprogrammed cells. However, proviral silencing, 
REX1, DNMT3B and ABCG2 gene expression and TRA-1-60 expression are 
validated markers that distinguish fully reprogrammed cells from partially 
reprogrammed cells (Chan et al., 2009). 
 
2.3       Transcription factor 
Transcription factor is a protein that either binds directly to DNA or 
facilitates the binding by adjacent region of protein (Schleif, 1988). Different 
transcription factors could bind to identical DNA sequence and the interaction of 
these transcription factors regulate the expression of downstream genes (Jaynes and 
O'Farrell, 1988). 
Spatial-temporal control of developmental genes in entire organisms is 
regulated by functional multiprotein complex formed from finite sets of transcription 
factors. Transcription factors have a propensity to cluster together at regulatory 
regions of downstream genes (Biggin, 2011, Kadonaga, 2004). The clustering of 
transcription factors on DNA motif is mediated through the interface of protein-
protein interaction of individual transcription factor (Ng et al., 2012). In spite of the 
regulation by finite sets of transcription factors, DNA consensus sequence also 
